ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Biotechnology

CRISPR gene editing wins Japan patent case

Ruling for US lab has potential to raise costs for drug and food development

A technician works with genome samples at a lab of the Chinese biotech company Sinogene, which specializes in dog cloning.   © Reuters

TOKYO -- A Japanese court ruled Tuesday in favor of a patent application by a U.S. institute on the breakthrough CRISPR-Cas9 gene-editing technique, in a win for a technology embroiled in intellectual property disputes worldwide.

If the ruling is upheld, drugmakers and other companies would be required to pay license fees to use the technique for commercial purposes.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more